PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9089581

New developments in adjuvants.

J J Donnelly
View original source ↗Export metadata ↓

Abstract

The development of improved methods for the production of vaccines have fostered the use of purified subunits in place of live attenuated and whole inactivated organisms. Greater understanding of immune mechanisms has stimulated efforts to design vaccines that elicit specific mechanisms of resistance to particular pathogens. Together these forces have driven a search for novel adjuvants with specific properties optimally suited to vaccines for particular diseases. At the First International Conference on Immunology and Aging, a mini-symposium was devoted to the topic of new adjuvants. This review and the following two papers summarize the proceedings of the mini-symposium and illustrate the potential for the development of new adjuvants of greater efficacy and specificity, and the complexities involved in bringing new discoveries in adjuvants from the laboratory to the clinic.

Explore related subjects

Adjuvants, ImmunologicAluminumAnimalsCytokinesDrug DesignEmulsionsHumansLipopolysaccharidesLiposomesPolymersSaponinsVaccinationVaccines, SyntheticJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J J Donnelly. 1997. New developments in adjuvants.. https://doi.org/10.1016/s0047-6374(96)01810-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo.

We investigated the effect of the steroid hormone dehydroepiandrosterone (DHEA) on the hepatic expression and activity of carcinogen-activating enzymes, the cytochromes P450 (CYP) 1A1, 1A2 and 1B1, in Sprague-Dawley rats. In animals fed DHEA at 200 or 400 mg/kg body weight every other day for 2 weeks prior to exposure to the aryl hydrocarbon dimethylbenz[a]anthracene (DMBA, 5 mg/kg), there was a dose-dependent decrease in hepatic CYP activity, as measured by ethoxyresorufin-O (EROD) assay, from 37.1 to 22.9 and 14.7 pmoles/min/10 microg microsomes, respectively. DHEA did not directly inhibit microsomal EROD activity, however, leading us to investigate its effects on enzyme expression. To test this, we examined protein and mRNA levels of the enzymes. Western blot for CYP1A1 and CYP1A2 showed that DHEA inhibited the increase in hepatic CYP1A1 and CYP1A2 enzyme levels that are normally induced by DMBA. DMBA-induced increase in expression of CYP1A1, CYP1A2 and CYP1B1 mRNA was similarly blunted in DHEA-treated animals. DHEA was also able to significantly reduce the basal expression of CYP1A1 and CYP1A2 but not of CYP1B1. These results indicate that DHEA regulates the expression and, hence, the activity of hepatic carcinogen-activating enzymes in vivo, and this may be an important mechanism of its chemopreventive activity.

Adjuvants, Immunologic↗
PubMed2003

Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12.

FVB-NeuN (N#202) female mice transgenic for the HER-2/neu protooncogene driven by the murine mammary tumor virus (MMTV) promoter develop mammary carcinomas with a progression from focal atypical hyperplasia to in situ carcinoma and to invasive carcinoma that closely resembles that of human neoplasia. Here we report that the combination of tamoxifen plus interleukin 12 (IL-12) results in a very effective prevention of mammary carcinogenesis, significantly higher than those obtained with either tamoxifen or IL-12 alone. At 1 year of age, 20% of control mice resulted tumor-free, whereas 80% of mice receiving the combined treatment were tumor-free. At 2 years of age, less than 5% of control mice were tumor-free, as opposed to 70% of mice treated with tamoxifen plus IL-12. The combined treatment inhibited mammary carcinogenesis mainly through a reduction in the number of mammary cells at risk of progression, a reduction in estrogen receptors (ERs) expression and a reduction in the angiogenic support to mammary development, likely due to cross-talk between tamoxifen and interferon-gamma (IFN-gamma) (the main downstream mediator elicited in vivo by IL-12). The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen.

Adjuvants, Immunologic↗
PubMed2003

Effects of cyanobacteria bloom extract on some parameters of immune function in mice.

Microcystis aeruginosa is a common cyanobacterium in water blooms that appear world widely in eutrophic freshwaters, and its toxic blooms have caused many death and illness cases. This paper presents the first data on the immunotoxicity of a microcystin (MC) extract of cyanobacteria bloom collected from Taihu Lake, China to BALB/c mice. The cyanobacteria bloom extract (CBE) containing MCs was administered by i.p. injection for 14 days at three sublethal doses of 16, 32, 64 mg lyophilized algae cells/kg body weight. Exposure to CBE decreased body weights dose-dependently. Meanwhile, liver body weight ratios were markedly increased. The significant differences were also observed in spleen and thymus body ratios upon the elevation of treatment dose comparing to control. CBE was also found to reduce the phagocytosis evaluated using phagocytic index of peritoneal phagocyte; this suppression was not evident in percentage phagocytosis. Treatment of CBE produced the inhibition of lipopolysaccharide-induced lymphoproliferation and the dose-dependent decrease of the numbers of antibody-forming cells in mice that were immunized by using T-dependent antigen sheep red blood cells. However, CBE did not affect concanavalin A-induced T cell proliferation. Our results demonstrate that exposure to CBE resulted in immunosuppression in mice.

Adjuvants, Immunologic↗